Product
131-MIBG + Vorinostat
1 clinical trial
3 indications
Indication
NeuroblastomaIndication
Neuroectodermal TumorsIndication
CancerClinical trial
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)Status: Recruiting, Estimated PCD: 2023-12-01